Astrana Health (NASDAQ:ASTH) Upgraded at Zacks Research

Zacks Research upgraded shares of Astrana Health (NASDAQ:ASTH) from a strong sell rating to a hold rating in a research report report published on Wednesday morning,Zacks.com reports.

Several other brokerages also recently issued reports on ASTH. Barclays lowered their price target on Astrana Health from $36.00 to $26.00 and set an “equal weight” rating for the company in a report on Monday, November 24th. BTIG Research decreased their price objective on Astrana Health from $45.00 to $40.00 and set a “buy” rating for the company in a research report on Monday, February 2nd. Needham & Company LLC started coverage on Astrana Health in a research note on Friday, December 12th. They set a “buy” rating and a $28.00 target price for the company. Jefferies Financial Group restated a “buy” rating on shares of Astrana Health in a report on Tuesday, November 25th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Astrana Health in a research note on Monday, December 29th. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $34.00.

Astrana Health Trading Up 4.3%

Shares of NASDAQ ASTH opened at $24.26 on Wednesday. The company’s fifty day moving average is $23.46 and its 200-day moving average is $25.99. The stock has a market cap of $1.37 billion, a price-to-earnings ratio of 52.74 and a beta of 0.91. Astrana Health has a twelve month low of $18.08 and a twelve month high of $34.80. The company has a quick ratio of 1.40, a current ratio of 1.40 and a debt-to-equity ratio of 1.25.

Astrana Health (NASDAQ:ASTH) last released its quarterly earnings data on Monday, March 2nd. The company reported $0.54 EPS for the quarter, beating analysts’ consensus estimates of $0.15 by $0.39. The business had revenue of $950.53 million during the quarter, compared to analysts’ expectations of $930.46 million. Astrana Health had a net margin of 0.71% and a return on equity of 5.59%. The firm’s quarterly revenue was up 42.9% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.15) EPS. Equities research analysts predict that Astrana Health will post 1.15 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ASTH. Signaturefd LLC raised its position in Astrana Health by 57.9% in the 4th quarter. Signaturefd LLC now owns 1,058 shares of the company’s stock valued at $26,000 after buying an additional 388 shares during the last quarter. Amalgamated Bank boosted its position in Astrana Health by 3.4% during the 3rd quarter. Amalgamated Bank now owns 12,325 shares of the company’s stock worth $349,000 after acquiring an additional 409 shares during the last quarter. Thrivent Financial for Lutherans grew its stake in shares of Astrana Health by 1.5% during the 3rd quarter. Thrivent Financial for Lutherans now owns 30,977 shares of the company’s stock worth $878,000 after acquiring an additional 455 shares in the last quarter. Principal Financial Group Inc. grew its stake in shares of Astrana Health by 0.3% during the 3rd quarter. Principal Financial Group Inc. now owns 222,985 shares of the company’s stock worth $6,322,000 after acquiring an additional 611 shares in the last quarter. Finally, Savant Capital LLC raised its holdings in shares of Astrana Health by 2.2% in the third quarter. Savant Capital LLC now owns 30,713 shares of the company’s stock valued at $871,000 after purchasing an additional 649 shares during the last quarter. 52.77% of the stock is owned by institutional investors and hedge funds.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.